Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

Executive Summary

FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.

Advertisement

Related Content

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press
Scoring Value: New Tools Challenge Pharma's US Pricing Bonanza

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel